Idhifa (enasidenib) — United Healthcare
Acute myeloid leukemia (AML) with an IDH2 mutation
Initial criteria
- Diagnosis of acute myeloid leukemia (AML)
- AML is IDH2 mutation-positive
- One of the following: disease is relapsed or refractory OR used as low-intensity treatment induction when not a candidate for intensive induction therapy OR used for consolidation therapy as continuation of low-intensity regimen used for induction OR used as follow-up after induction therapy following response to previous lower intensity therapy with the same regimen
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Idhifa therapy
Approval duration
12 months